Fig. 2From: A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosisIndividual patient modified Rodnan skin scores at 0, 6 and 12 months of the studyBack to article page